<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE LCTL_TEXT SYSTEM "ltf.v1.5.dtd">
<LCTL_TEXT lang="spa">
<DOC id="L0C04CVO2" lang="spa" tokenization="tokenization_parameters.v5.0" grammar="none" raw_text_char_length="2896" raw_text_md5="f60acddd70f4e8cb2cdc0c5ceeef11e2">
<TEXT>
<SEG id="segment-0" start_char="1" end_char="65">
<ORIGINAL_TEXT>Study Findings Do Not Support Use of Ivermectin for Mild COVID-19</ORIGINAL_TEXT>
<TOKEN id="token-0-0" pos="word" morph="none" start_char="1" end_char="5">Study</TOKEN>
<TOKEN id="token-0-1" pos="word" morph="none" start_char="7" end_char="14">Findings</TOKEN>
<TOKEN id="token-0-2" pos="word" morph="none" start_char="16" end_char="17">Do</TOKEN>
<TOKEN id="token-0-3" pos="word" morph="none" start_char="19" end_char="21">Not</TOKEN>
<TOKEN id="token-0-4" pos="word" morph="none" start_char="23" end_char="29">Support</TOKEN>
<TOKEN id="token-0-5" pos="word" morph="none" start_char="31" end_char="33">Use</TOKEN>
<TOKEN id="token-0-6" pos="word" morph="none" start_char="35" end_char="36">of</TOKEN>
<TOKEN id="token-0-7" pos="word" morph="none" start_char="38" end_char="47">Ivermectin</TOKEN>
<TOKEN id="token-0-8" pos="word" morph="none" start_char="49" end_char="51">for</TOKEN>
<TOKEN id="token-0-9" pos="word" morph="none" start_char="53" end_char="56">Mild</TOKEN>
<TOKEN id="token-0-10" pos="unknown" morph="none" start_char="58" end_char="65">COVID-19</TOKEN>
</SEG>
<SEG id="segment-1" start_char="69" end_char="175">
<ORIGINAL_TEXT>Patients with mild COVID-19 symptoms were administered ivermectin 0.6% oral solution or placebo for 5 days.</ORIGINAL_TEXT>
<TOKEN id="token-1-0" pos="word" morph="none" start_char="69" end_char="76">Patients</TOKEN>
<TOKEN id="token-1-1" pos="word" morph="none" start_char="78" end_char="81">with</TOKEN>
<TOKEN id="token-1-2" pos="word" morph="none" start_char="83" end_char="86">mild</TOKEN>
<TOKEN id="token-1-3" pos="unknown" morph="none" start_char="88" end_char="95">COVID-19</TOKEN>
<TOKEN id="token-1-4" pos="word" morph="none" start_char="97" end_char="104">symptoms</TOKEN>
<TOKEN id="token-1-5" pos="word" morph="none" start_char="106" end_char="109">were</TOKEN>
<TOKEN id="token-1-6" pos="word" morph="none" start_char="111" end_char="122">administered</TOKEN>
<TOKEN id="token-1-7" pos="word" morph="none" start_char="124" end_char="133">ivermectin</TOKEN>
<TOKEN id="token-1-8" pos="unknown" morph="none" start_char="135" end_char="137">0.6</TOKEN>
<TOKEN id="token-1-9" pos="punct" morph="none" start_char="138" end_char="138">%</TOKEN>
<TOKEN id="token-1-10" pos="word" morph="none" start_char="140" end_char="143">oral</TOKEN>
<TOKEN id="token-1-11" pos="word" morph="none" start_char="145" end_char="152">solution</TOKEN>
<TOKEN id="token-1-12" pos="word" morph="none" start_char="154" end_char="155">or</TOKEN>
<TOKEN id="token-1-13" pos="word" morph="none" start_char="157" end_char="163">placebo</TOKEN>
<TOKEN id="token-1-14" pos="word" morph="none" start_char="165" end_char="167">for</TOKEN>
<TOKEN id="token-1-15" pos="word" morph="none" start_char="169" end_char="169">5</TOKEN>
<TOKEN id="token-1-16" pos="word" morph="none" start_char="171" end_char="174">days</TOKEN>
<TOKEN id="token-1-17" pos="punct" morph="none" start_char="175" end_char="175">.</TOKEN>
</SEG>
<SEG id="segment-2" start_char="179" end_char="392">
<ORIGINAL_TEXT>The use of ivermectin does not appear to significantly shorten the duration of symptoms in patients with mild coronavirus disease 2019 (COVID-19), according to findings from a randomized clinical trial published in</ORIGINAL_TEXT>
<TOKEN id="token-2-0" pos="word" morph="none" start_char="179" end_char="181">The</TOKEN>
<TOKEN id="token-2-1" pos="word" morph="none" start_char="183" end_char="185">use</TOKEN>
<TOKEN id="token-2-2" pos="word" morph="none" start_char="187" end_char="188">of</TOKEN>
<TOKEN id="token-2-3" pos="word" morph="none" start_char="190" end_char="199">ivermectin</TOKEN>
<TOKEN id="token-2-4" pos="word" morph="none" start_char="201" end_char="204">does</TOKEN>
<TOKEN id="token-2-5" pos="word" morph="none" start_char="206" end_char="208">not</TOKEN>
<TOKEN id="token-2-6" pos="word" morph="none" start_char="210" end_char="215">appear</TOKEN>
<TOKEN id="token-2-7" pos="word" morph="none" start_char="217" end_char="218">to</TOKEN>
<TOKEN id="token-2-8" pos="word" morph="none" start_char="220" end_char="232">significantly</TOKEN>
<TOKEN id="token-2-9" pos="word" morph="none" start_char="234" end_char="240">shorten</TOKEN>
<TOKEN id="token-2-10" pos="word" morph="none" start_char="242" end_char="244">the</TOKEN>
<TOKEN id="token-2-11" pos="word" morph="none" start_char="246" end_char="253">duration</TOKEN>
<TOKEN id="token-2-12" pos="word" morph="none" start_char="255" end_char="256">of</TOKEN>
<TOKEN id="token-2-13" pos="word" morph="none" start_char="258" end_char="265">symptoms</TOKEN>
<TOKEN id="token-2-14" pos="word" morph="none" start_char="267" end_char="268">in</TOKEN>
<TOKEN id="token-2-15" pos="word" morph="none" start_char="270" end_char="277">patients</TOKEN>
<TOKEN id="token-2-16" pos="word" morph="none" start_char="279" end_char="282">with</TOKEN>
<TOKEN id="token-2-17" pos="word" morph="none" start_char="284" end_char="287">mild</TOKEN>
<TOKEN id="token-2-18" pos="word" morph="none" start_char="289" end_char="299">coronavirus</TOKEN>
<TOKEN id="token-2-19" pos="word" morph="none" start_char="301" end_char="307">disease</TOKEN>
<TOKEN id="token-2-20" pos="word" morph="none" start_char="309" end_char="312">2019</TOKEN>
<TOKEN id="token-2-21" pos="punct" morph="none" start_char="314" end_char="314">(</TOKEN>
<TOKEN id="token-2-22" pos="unknown" morph="none" start_char="315" end_char="322">COVID-19</TOKEN>
<TOKEN id="token-2-23" pos="punct" morph="none" start_char="323" end_char="324">),</TOKEN>
<TOKEN id="token-2-24" pos="word" morph="none" start_char="326" end_char="334">according</TOKEN>
<TOKEN id="token-2-25" pos="word" morph="none" start_char="336" end_char="337">to</TOKEN>
<TOKEN id="token-2-26" pos="word" morph="none" start_char="339" end_char="346">findings</TOKEN>
<TOKEN id="token-2-27" pos="word" morph="none" start_char="348" end_char="351">from</TOKEN>
<TOKEN id="token-2-28" pos="word" morph="none" start_char="353" end_char="353">a</TOKEN>
<TOKEN id="token-2-29" pos="word" morph="none" start_char="355" end_char="364">randomized</TOKEN>
<TOKEN id="token-2-30" pos="word" morph="none" start_char="366" end_char="373">clinical</TOKEN>
<TOKEN id="token-2-31" pos="word" morph="none" start_char="375" end_char="379">trial</TOKEN>
<TOKEN id="token-2-32" pos="word" morph="none" start_char="381" end_char="389">published</TOKEN>
<TOKEN id="token-2-33" pos="word" morph="none" start_char="391" end_char="392">in</TOKEN>
</SEG>
<SEG id="segment-3" start_char="395" end_char="398">
<ORIGINAL_TEXT>JAMA</ORIGINAL_TEXT>
<TOKEN id="token-3-0" pos="word" morph="none" start_char="395" end_char="398">JAMA</TOKEN>
</SEG>
<SEG id="segment-4" start_char="401" end_char="401">
<ORIGINAL_TEXT>.</ORIGINAL_TEXT>
<TOKEN id="token-4-0" pos="punct" morph="none" start_char="401" end_char="401">.</TOKEN>
</SEG>
<SEG id="segment-5" start_char="404" end_char="606">
<ORIGINAL_TEXT>Ivermectin, an antiparasitic agent, continues to be widely used as a potential treatment for COVID-19 based on experimental studies showing antiviral activity during the early stages of other infections.</ORIGINAL_TEXT>
<TOKEN id="token-5-0" pos="word" morph="none" start_char="404" end_char="413">Ivermectin</TOKEN>
<TOKEN id="token-5-1" pos="punct" morph="none" start_char="414" end_char="414">,</TOKEN>
<TOKEN id="token-5-2" pos="word" morph="none" start_char="416" end_char="417">an</TOKEN>
<TOKEN id="token-5-3" pos="word" morph="none" start_char="419" end_char="431">antiparasitic</TOKEN>
<TOKEN id="token-5-4" pos="word" morph="none" start_char="433" end_char="437">agent</TOKEN>
<TOKEN id="token-5-5" pos="punct" morph="none" start_char="438" end_char="438">,</TOKEN>
<TOKEN id="token-5-6" pos="word" morph="none" start_char="440" end_char="448">continues</TOKEN>
<TOKEN id="token-5-7" pos="word" morph="none" start_char="450" end_char="451">to</TOKEN>
<TOKEN id="token-5-8" pos="word" morph="none" start_char="453" end_char="454">be</TOKEN>
<TOKEN id="token-5-9" pos="word" morph="none" start_char="456" end_char="461">widely</TOKEN>
<TOKEN id="token-5-10" pos="word" morph="none" start_char="463" end_char="466">used</TOKEN>
<TOKEN id="token-5-11" pos="word" morph="none" start_char="468" end_char="469">as</TOKEN>
<TOKEN id="token-5-12" pos="word" morph="none" start_char="471" end_char="471">a</TOKEN>
<TOKEN id="token-5-13" pos="word" morph="none" start_char="473" end_char="481">potential</TOKEN>
<TOKEN id="token-5-14" pos="word" morph="none" start_char="483" end_char="491">treatment</TOKEN>
<TOKEN id="token-5-15" pos="word" morph="none" start_char="493" end_char="495">for</TOKEN>
<TOKEN id="token-5-16" pos="unknown" morph="none" start_char="497" end_char="504">COVID-19</TOKEN>
<TOKEN id="token-5-17" pos="word" morph="none" start_char="506" end_char="510">based</TOKEN>
<TOKEN id="token-5-18" pos="word" morph="none" start_char="512" end_char="513">on</TOKEN>
<TOKEN id="token-5-19" pos="word" morph="none" start_char="515" end_char="526">experimental</TOKEN>
<TOKEN id="token-5-20" pos="word" morph="none" start_char="528" end_char="534">studies</TOKEN>
<TOKEN id="token-5-21" pos="word" morph="none" start_char="536" end_char="542">showing</TOKEN>
<TOKEN id="token-5-22" pos="word" morph="none" start_char="544" end_char="552">antiviral</TOKEN>
<TOKEN id="token-5-23" pos="word" morph="none" start_char="554" end_char="561">activity</TOKEN>
<TOKEN id="token-5-24" pos="word" morph="none" start_char="563" end_char="568">during</TOKEN>
<TOKEN id="token-5-25" pos="word" morph="none" start_char="570" end_char="572">the</TOKEN>
<TOKEN id="token-5-26" pos="word" morph="none" start_char="574" end_char="578">early</TOKEN>
<TOKEN id="token-5-27" pos="word" morph="none" start_char="580" end_char="585">stages</TOKEN>
<TOKEN id="token-5-28" pos="word" morph="none" start_char="587" end_char="588">of</TOKEN>
<TOKEN id="token-5-29" pos="word" morph="none" start_char="590" end_char="594">other</TOKEN>
<TOKEN id="token-5-30" pos="word" morph="none" start_char="596" end_char="605">infections</TOKEN>
<TOKEN id="token-5-31" pos="punct" morph="none" start_char="606" end_char="606">.</TOKEN>
</SEG>
<SEG id="segment-6" start_char="608" end_char="818">
<ORIGINAL_TEXT>To assess its effect on the duration of symptoms in patients with mild COVID-19, the study authors conducted a double-blind, randomized trial in a single site in Cali, Colombia (ClinicalTrials.gov: NCT04405843).</ORIGINAL_TEXT>
<TOKEN id="token-6-0" pos="word" morph="none" start_char="608" end_char="609">To</TOKEN>
<TOKEN id="token-6-1" pos="word" morph="none" start_char="611" end_char="616">assess</TOKEN>
<TOKEN id="token-6-2" pos="word" morph="none" start_char="618" end_char="620">its</TOKEN>
<TOKEN id="token-6-3" pos="word" morph="none" start_char="622" end_char="627">effect</TOKEN>
<TOKEN id="token-6-4" pos="word" morph="none" start_char="629" end_char="630">on</TOKEN>
<TOKEN id="token-6-5" pos="word" morph="none" start_char="632" end_char="634">the</TOKEN>
<TOKEN id="token-6-6" pos="word" morph="none" start_char="636" end_char="643">duration</TOKEN>
<TOKEN id="token-6-7" pos="word" morph="none" start_char="645" end_char="646">of</TOKEN>
<TOKEN id="token-6-8" pos="word" morph="none" start_char="648" end_char="655">symptoms</TOKEN>
<TOKEN id="token-6-9" pos="word" morph="none" start_char="657" end_char="658">in</TOKEN>
<TOKEN id="token-6-10" pos="word" morph="none" start_char="660" end_char="667">patients</TOKEN>
<TOKEN id="token-6-11" pos="word" morph="none" start_char="669" end_char="672">with</TOKEN>
<TOKEN id="token-6-12" pos="word" morph="none" start_char="674" end_char="677">mild</TOKEN>
<TOKEN id="token-6-13" pos="unknown" morph="none" start_char="679" end_char="686">COVID-19</TOKEN>
<TOKEN id="token-6-14" pos="punct" morph="none" start_char="687" end_char="687">,</TOKEN>
<TOKEN id="token-6-15" pos="word" morph="none" start_char="689" end_char="691">the</TOKEN>
<TOKEN id="token-6-16" pos="word" morph="none" start_char="693" end_char="697">study</TOKEN>
<TOKEN id="token-6-17" pos="word" morph="none" start_char="699" end_char="705">authors</TOKEN>
<TOKEN id="token-6-18" pos="word" morph="none" start_char="707" end_char="715">conducted</TOKEN>
<TOKEN id="token-6-19" pos="word" morph="none" start_char="717" end_char="717">a</TOKEN>
<TOKEN id="token-6-20" pos="unknown" morph="none" start_char="719" end_char="730">double-blind</TOKEN>
<TOKEN id="token-6-21" pos="punct" morph="none" start_char="731" end_char="731">,</TOKEN>
<TOKEN id="token-6-22" pos="word" morph="none" start_char="733" end_char="742">randomized</TOKEN>
<TOKEN id="token-6-23" pos="word" morph="none" start_char="744" end_char="748">trial</TOKEN>
<TOKEN id="token-6-24" pos="word" morph="none" start_char="750" end_char="751">in</TOKEN>
<TOKEN id="token-6-25" pos="word" morph="none" start_char="753" end_char="753">a</TOKEN>
<TOKEN id="token-6-26" pos="word" morph="none" start_char="755" end_char="760">single</TOKEN>
<TOKEN id="token-6-27" pos="word" morph="none" start_char="762" end_char="765">site</TOKEN>
<TOKEN id="token-6-28" pos="word" morph="none" start_char="767" end_char="768">in</TOKEN>
<TOKEN id="token-6-29" pos="word" morph="none" start_char="770" end_char="773">Cali</TOKEN>
<TOKEN id="token-6-30" pos="punct" morph="none" start_char="774" end_char="774">,</TOKEN>
<TOKEN id="token-6-31" pos="word" morph="none" start_char="776" end_char="783">Colombia</TOKEN>
<TOKEN id="token-6-32" pos="punct" morph="none" start_char="785" end_char="785">(</TOKEN>
<TOKEN id="token-6-33" pos="unknown" morph="none" start_char="786" end_char="803">ClinicalTrials.gov</TOKEN>
<TOKEN id="token-6-34" pos="punct" morph="none" start_char="804" end_char="804">:</TOKEN>
<TOKEN id="token-6-35" pos="word" morph="none" start_char="806" end_char="816">NCT04405843</TOKEN>
<TOKEN id="token-6-36" pos="punct" morph="none" start_char="817" end_char="818">).</TOKEN>
</SEG>
<SEG id="segment-7" start_char="821" end_char="1009">
<ORIGINAL_TEXT>Using the state’s health department electronic database, study participants were selected if they had laboratory-confirmed COVID-19 with mild disease and symptom duration of 7 days or less.</ORIGINAL_TEXT>
<TOKEN id="token-7-0" pos="word" morph="none" start_char="821" end_char="825">Using</TOKEN>
<TOKEN id="token-7-1" pos="word" morph="none" start_char="827" end_char="829">the</TOKEN>
<TOKEN id="token-7-2" pos="word" morph="none" start_char="831" end_char="837">state’s</TOKEN>
<TOKEN id="token-7-3" pos="word" morph="none" start_char="839" end_char="844">health</TOKEN>
<TOKEN id="token-7-4" pos="word" morph="none" start_char="846" end_char="855">department</TOKEN>
<TOKEN id="token-7-5" pos="word" morph="none" start_char="857" end_char="866">electronic</TOKEN>
<TOKEN id="token-7-6" pos="word" morph="none" start_char="868" end_char="875">database</TOKEN>
<TOKEN id="token-7-7" pos="punct" morph="none" start_char="876" end_char="876">,</TOKEN>
<TOKEN id="token-7-8" pos="word" morph="none" start_char="878" end_char="882">study</TOKEN>
<TOKEN id="token-7-9" pos="word" morph="none" start_char="884" end_char="895">participants</TOKEN>
<TOKEN id="token-7-10" pos="word" morph="none" start_char="897" end_char="900">were</TOKEN>
<TOKEN id="token-7-11" pos="word" morph="none" start_char="902" end_char="909">selected</TOKEN>
<TOKEN id="token-7-12" pos="word" morph="none" start_char="911" end_char="912">if</TOKEN>
<TOKEN id="token-7-13" pos="word" morph="none" start_char="914" end_char="917">they</TOKEN>
<TOKEN id="token-7-14" pos="word" morph="none" start_char="919" end_char="921">had</TOKEN>
<TOKEN id="token-7-15" pos="unknown" morph="none" start_char="923" end_char="942">laboratory-confirmed</TOKEN>
<TOKEN id="token-7-16" pos="unknown" morph="none" start_char="944" end_char="951">COVID-19</TOKEN>
<TOKEN id="token-7-17" pos="word" morph="none" start_char="953" end_char="956">with</TOKEN>
<TOKEN id="token-7-18" pos="word" morph="none" start_char="958" end_char="961">mild</TOKEN>
<TOKEN id="token-7-19" pos="word" morph="none" start_char="963" end_char="969">disease</TOKEN>
<TOKEN id="token-7-20" pos="word" morph="none" start_char="971" end_char="973">and</TOKEN>
<TOKEN id="token-7-21" pos="word" morph="none" start_char="975" end_char="981">symptom</TOKEN>
<TOKEN id="token-7-22" pos="word" morph="none" start_char="983" end_char="990">duration</TOKEN>
<TOKEN id="token-7-23" pos="word" morph="none" start_char="992" end_char="993">of</TOKEN>
<TOKEN id="token-7-24" pos="word" morph="none" start_char="995" end_char="995">7</TOKEN>
<TOKEN id="token-7-25" pos="word" morph="none" start_char="997" end_char="1000">days</TOKEN>
<TOKEN id="token-7-26" pos="word" morph="none" start_char="1002" end_char="1003">or</TOKEN>
<TOKEN id="token-7-27" pos="word" morph="none" start_char="1005" end_char="1008">less</TOKEN>
<TOKEN id="token-7-28" pos="punct" morph="none" start_char="1009" end_char="1009">.</TOKEN>
</SEG>
<SEG id="segment-8" start_char="1011" end_char="1232">
<ORIGINAL_TEXT>A total of 476 adults were enrolled and 400 (the primary analysis population; median age, 37 years; 58% women) were randomly assigned to receive ivermectin 300μg/kg of body weight/day for 5 days (n=200) or placebo (n=200).</ORIGINAL_TEXT>
<TOKEN id="token-8-0" pos="word" morph="none" start_char="1011" end_char="1011">A</TOKEN>
<TOKEN id="token-8-1" pos="word" morph="none" start_char="1013" end_char="1017">total</TOKEN>
<TOKEN id="token-8-2" pos="word" morph="none" start_char="1019" end_char="1020">of</TOKEN>
<TOKEN id="token-8-3" pos="word" morph="none" start_char="1022" end_char="1024">476</TOKEN>
<TOKEN id="token-8-4" pos="word" morph="none" start_char="1026" end_char="1031">adults</TOKEN>
<TOKEN id="token-8-5" pos="word" morph="none" start_char="1033" end_char="1036">were</TOKEN>
<TOKEN id="token-8-6" pos="word" morph="none" start_char="1038" end_char="1045">enrolled</TOKEN>
<TOKEN id="token-8-7" pos="word" morph="none" start_char="1047" end_char="1049">and</TOKEN>
<TOKEN id="token-8-8" pos="word" morph="none" start_char="1051" end_char="1053">400</TOKEN>
<TOKEN id="token-8-9" pos="punct" morph="none" start_char="1055" end_char="1055">(</TOKEN>
<TOKEN id="token-8-10" pos="word" morph="none" start_char="1056" end_char="1058">the</TOKEN>
<TOKEN id="token-8-11" pos="word" morph="none" start_char="1060" end_char="1066">primary</TOKEN>
<TOKEN id="token-8-12" pos="word" morph="none" start_char="1068" end_char="1075">analysis</TOKEN>
<TOKEN id="token-8-13" pos="word" morph="none" start_char="1077" end_char="1086">population</TOKEN>
<TOKEN id="token-8-14" pos="punct" morph="none" start_char="1087" end_char="1087">;</TOKEN>
<TOKEN id="token-8-15" pos="word" morph="none" start_char="1089" end_char="1094">median</TOKEN>
<TOKEN id="token-8-16" pos="word" morph="none" start_char="1096" end_char="1098">age</TOKEN>
<TOKEN id="token-8-17" pos="punct" morph="none" start_char="1099" end_char="1099">,</TOKEN>
<TOKEN id="token-8-18" pos="word" morph="none" start_char="1101" end_char="1102">37</TOKEN>
<TOKEN id="token-8-19" pos="word" morph="none" start_char="1104" end_char="1108">years</TOKEN>
<TOKEN id="token-8-20" pos="punct" morph="none" start_char="1109" end_char="1109">;</TOKEN>
<TOKEN id="token-8-21" pos="word" morph="none" start_char="1111" end_char="1112">58</TOKEN>
<TOKEN id="token-8-22" pos="punct" morph="none" start_char="1113" end_char="1113">%</TOKEN>
<TOKEN id="token-8-23" pos="word" morph="none" start_char="1115" end_char="1119">women</TOKEN>
<TOKEN id="token-8-24" pos="punct" morph="none" start_char="1120" end_char="1120">)</TOKEN>
<TOKEN id="token-8-25" pos="word" morph="none" start_char="1122" end_char="1125">were</TOKEN>
<TOKEN id="token-8-26" pos="word" morph="none" start_char="1127" end_char="1134">randomly</TOKEN>
<TOKEN id="token-8-27" pos="word" morph="none" start_char="1136" end_char="1143">assigned</TOKEN>
<TOKEN id="token-8-28" pos="word" morph="none" start_char="1145" end_char="1146">to</TOKEN>
<TOKEN id="token-8-29" pos="word" morph="none" start_char="1148" end_char="1154">receive</TOKEN>
<TOKEN id="token-8-30" pos="word" morph="none" start_char="1156" end_char="1165">ivermectin</TOKEN>
<TOKEN id="token-8-31" pos="unknown" morph="none" start_char="1167" end_char="1174">300μg/kg</TOKEN>
<TOKEN id="token-8-32" pos="word" morph="none" start_char="1176" end_char="1177">of</TOKEN>
<TOKEN id="token-8-33" pos="word" morph="none" start_char="1179" end_char="1182">body</TOKEN>
<TOKEN id="token-8-34" pos="unknown" morph="none" start_char="1184" end_char="1193">weight/day</TOKEN>
<TOKEN id="token-8-35" pos="word" morph="none" start_char="1195" end_char="1197">for</TOKEN>
<TOKEN id="token-8-36" pos="word" morph="none" start_char="1199" end_char="1199">5</TOKEN>
<TOKEN id="token-8-37" pos="word" morph="none" start_char="1201" end_char="1204">days</TOKEN>
<TOKEN id="token-8-38" pos="punct" morph="none" start_char="1206" end_char="1206">(</TOKEN>
<TOKEN id="token-8-39" pos="unknown" morph="none" start_char="1207" end_char="1211">n=200</TOKEN>
<TOKEN id="token-8-40" pos="punct" morph="none" start_char="1212" end_char="1212">)</TOKEN>
<TOKEN id="token-8-41" pos="word" morph="none" start_char="1214" end_char="1215">or</TOKEN>
<TOKEN id="token-8-42" pos="word" morph="none" start_char="1217" end_char="1223">placebo</TOKEN>
<TOKEN id="token-8-43" pos="punct" morph="none" start_char="1225" end_char="1225">(</TOKEN>
<TOKEN id="token-8-44" pos="unknown" morph="none" start_char="1226" end_char="1230">n=200</TOKEN>
<TOKEN id="token-8-45" pos="punct" morph="none" start_char="1231" end_char="1232">).</TOKEN>
</SEG>
<SEG id="segment-9" start_char="1234" end_char="1366">
<ORIGINAL_TEXT>The primary outcome measure of the study was the time to complete resolution of COVID-19 symptoms within the 21-day follow-up period.</ORIGINAL_TEXT>
<TOKEN id="token-9-0" pos="word" morph="none" start_char="1234" end_char="1236">The</TOKEN>
<TOKEN id="token-9-1" pos="word" morph="none" start_char="1238" end_char="1244">primary</TOKEN>
<TOKEN id="token-9-2" pos="word" morph="none" start_char="1246" end_char="1252">outcome</TOKEN>
<TOKEN id="token-9-3" pos="word" morph="none" start_char="1254" end_char="1260">measure</TOKEN>
<TOKEN id="token-9-4" pos="word" morph="none" start_char="1262" end_char="1263">of</TOKEN>
<TOKEN id="token-9-5" pos="word" morph="none" start_char="1265" end_char="1267">the</TOKEN>
<TOKEN id="token-9-6" pos="word" morph="none" start_char="1269" end_char="1273">study</TOKEN>
<TOKEN id="token-9-7" pos="word" morph="none" start_char="1275" end_char="1277">was</TOKEN>
<TOKEN id="token-9-8" pos="word" morph="none" start_char="1279" end_char="1281">the</TOKEN>
<TOKEN id="token-9-9" pos="word" morph="none" start_char="1283" end_char="1286">time</TOKEN>
<TOKEN id="token-9-10" pos="word" morph="none" start_char="1288" end_char="1289">to</TOKEN>
<TOKEN id="token-9-11" pos="word" morph="none" start_char="1291" end_char="1298">complete</TOKEN>
<TOKEN id="token-9-12" pos="word" morph="none" start_char="1300" end_char="1309">resolution</TOKEN>
<TOKEN id="token-9-13" pos="word" morph="none" start_char="1311" end_char="1312">of</TOKEN>
<TOKEN id="token-9-14" pos="unknown" morph="none" start_char="1314" end_char="1321">COVID-19</TOKEN>
<TOKEN id="token-9-15" pos="word" morph="none" start_char="1323" end_char="1330">symptoms</TOKEN>
<TOKEN id="token-9-16" pos="word" morph="none" start_char="1332" end_char="1337">within</TOKEN>
<TOKEN id="token-9-17" pos="word" morph="none" start_char="1339" end_char="1341">the</TOKEN>
<TOKEN id="token-9-18" pos="unknown" morph="none" start_char="1343" end_char="1348">21-day</TOKEN>
<TOKEN id="token-9-19" pos="unknown" morph="none" start_char="1350" end_char="1358">follow-up</TOKEN>
<TOKEN id="token-9-20" pos="word" morph="none" start_char="1360" end_char="1365">period</TOKEN>
<TOKEN id="token-9-21" pos="punct" morph="none" start_char="1366" end_char="1366">.</TOKEN>
</SEG>
<SEG id="segment-10" start_char="1369" end_char="1660">
<ORIGINAL_TEXT>Among the 398 patients that completed the trial, results showed the median time to resolution of COVID-19 symptoms was 10 days (interquartile range [IQR], 9-13) for patients who received ivermectin and 12 days (IQR, 9-13) for those who received placebo (hazard ratio 1.07 [95% CI, 0.87-1.32];</ORIGINAL_TEXT>
<TOKEN id="token-10-0" pos="word" morph="none" start_char="1369" end_char="1373">Among</TOKEN>
<TOKEN id="token-10-1" pos="word" morph="none" start_char="1375" end_char="1377">the</TOKEN>
<TOKEN id="token-10-2" pos="word" morph="none" start_char="1379" end_char="1381">398</TOKEN>
<TOKEN id="token-10-3" pos="word" morph="none" start_char="1383" end_char="1390">patients</TOKEN>
<TOKEN id="token-10-4" pos="word" morph="none" start_char="1392" end_char="1395">that</TOKEN>
<TOKEN id="token-10-5" pos="word" morph="none" start_char="1397" end_char="1405">completed</TOKEN>
<TOKEN id="token-10-6" pos="word" morph="none" start_char="1407" end_char="1409">the</TOKEN>
<TOKEN id="token-10-7" pos="word" morph="none" start_char="1411" end_char="1415">trial</TOKEN>
<TOKEN id="token-10-8" pos="punct" morph="none" start_char="1416" end_char="1416">,</TOKEN>
<TOKEN id="token-10-9" pos="word" morph="none" start_char="1418" end_char="1424">results</TOKEN>
<TOKEN id="token-10-10" pos="word" morph="none" start_char="1426" end_char="1431">showed</TOKEN>
<TOKEN id="token-10-11" pos="word" morph="none" start_char="1433" end_char="1435">the</TOKEN>
<TOKEN id="token-10-12" pos="word" morph="none" start_char="1437" end_char="1442">median</TOKEN>
<TOKEN id="token-10-13" pos="word" morph="none" start_char="1444" end_char="1447">time</TOKEN>
<TOKEN id="token-10-14" pos="word" morph="none" start_char="1449" end_char="1450">to</TOKEN>
<TOKEN id="token-10-15" pos="word" morph="none" start_char="1452" end_char="1461">resolution</TOKEN>
<TOKEN id="token-10-16" pos="word" morph="none" start_char="1463" end_char="1464">of</TOKEN>
<TOKEN id="token-10-17" pos="unknown" morph="none" start_char="1466" end_char="1473">COVID-19</TOKEN>
<TOKEN id="token-10-18" pos="word" morph="none" start_char="1475" end_char="1482">symptoms</TOKEN>
<TOKEN id="token-10-19" pos="word" morph="none" start_char="1484" end_char="1486">was</TOKEN>
<TOKEN id="token-10-20" pos="word" morph="none" start_char="1488" end_char="1489">10</TOKEN>
<TOKEN id="token-10-21" pos="word" morph="none" start_char="1491" end_char="1494">days</TOKEN>
<TOKEN id="token-10-22" pos="punct" morph="none" start_char="1496" end_char="1496">(</TOKEN>
<TOKEN id="token-10-23" pos="word" morph="none" start_char="1497" end_char="1509">interquartile</TOKEN>
<TOKEN id="token-10-24" pos="word" morph="none" start_char="1511" end_char="1515">range</TOKEN>
<TOKEN id="token-10-25" pos="punct" morph="none" start_char="1517" end_char="1517">[</TOKEN>
<TOKEN id="token-10-26" pos="word" morph="none" start_char="1518" end_char="1520">IQR</TOKEN>
<TOKEN id="token-10-27" pos="punct" morph="none" start_char="1521" end_char="1522">],</TOKEN>
<TOKEN id="token-10-28" pos="unknown" morph="none" start_char="1524" end_char="1527">9-13</TOKEN>
<TOKEN id="token-10-29" pos="punct" morph="none" start_char="1528" end_char="1528">)</TOKEN>
<TOKEN id="token-10-30" pos="word" morph="none" start_char="1530" end_char="1532">for</TOKEN>
<TOKEN id="token-10-31" pos="word" morph="none" start_char="1534" end_char="1541">patients</TOKEN>
<TOKEN id="token-10-32" pos="word" morph="none" start_char="1543" end_char="1545">who</TOKEN>
<TOKEN id="token-10-33" pos="word" morph="none" start_char="1547" end_char="1554">received</TOKEN>
<TOKEN id="token-10-34" pos="word" morph="none" start_char="1556" end_char="1565">ivermectin</TOKEN>
<TOKEN id="token-10-35" pos="word" morph="none" start_char="1567" end_char="1569">and</TOKEN>
<TOKEN id="token-10-36" pos="word" morph="none" start_char="1571" end_char="1572">12</TOKEN>
<TOKEN id="token-10-37" pos="word" morph="none" start_char="1574" end_char="1577">days</TOKEN>
<TOKEN id="token-10-38" pos="punct" morph="none" start_char="1579" end_char="1579">(</TOKEN>
<TOKEN id="token-10-39" pos="word" morph="none" start_char="1580" end_char="1582">IQR</TOKEN>
<TOKEN id="token-10-40" pos="punct" morph="none" start_char="1583" end_char="1583">,</TOKEN>
<TOKEN id="token-10-41" pos="unknown" morph="none" start_char="1585" end_char="1588">9-13</TOKEN>
<TOKEN id="token-10-42" pos="punct" morph="none" start_char="1589" end_char="1589">)</TOKEN>
<TOKEN id="token-10-43" pos="word" morph="none" start_char="1591" end_char="1593">for</TOKEN>
<TOKEN id="token-10-44" pos="word" morph="none" start_char="1595" end_char="1599">those</TOKEN>
<TOKEN id="token-10-45" pos="word" morph="none" start_char="1601" end_char="1603">who</TOKEN>
<TOKEN id="token-10-46" pos="word" morph="none" start_char="1605" end_char="1612">received</TOKEN>
<TOKEN id="token-10-47" pos="word" morph="none" start_char="1614" end_char="1620">placebo</TOKEN>
<TOKEN id="token-10-48" pos="punct" morph="none" start_char="1622" end_char="1622">(</TOKEN>
<TOKEN id="token-10-49" pos="word" morph="none" start_char="1623" end_char="1628">hazard</TOKEN>
<TOKEN id="token-10-50" pos="word" morph="none" start_char="1630" end_char="1634">ratio</TOKEN>
<TOKEN id="token-10-51" pos="word" morph="none" start_char="1636" end_char="1639">1.07</TOKEN>
<TOKEN id="token-10-52" pos="punct" morph="none" start_char="1641" end_char="1641">[</TOKEN>
<TOKEN id="token-10-53" pos="word" morph="none" start_char="1642" end_char="1643">95</TOKEN>
<TOKEN id="token-10-54" pos="punct" morph="none" start_char="1644" end_char="1644">%</TOKEN>
<TOKEN id="token-10-55" pos="word" morph="none" start_char="1646" end_char="1647">CI</TOKEN>
<TOKEN id="token-10-56" pos="punct" morph="none" start_char="1648" end_char="1648">,</TOKEN>
<TOKEN id="token-10-57" pos="unknown" morph="none" start_char="1650" end_char="1658">0.87-1.32</TOKEN>
<TOKEN id="token-10-58" pos="punct" morph="none" start_char="1659" end_char="1660">];</TOKEN>
</SEG>
<SEG id="segment-11" start_char="1663" end_char="1663">
<ORIGINAL_TEXT>P</ORIGINAL_TEXT>
<TOKEN id="token-11-0" pos="word" morph="none" start_char="1663" end_char="1663">P</TOKEN>
</SEG>
<SEG id="segment-12" start_char="1666" end_char="1671">
<ORIGINAL_TEXT>=.53).</ORIGINAL_TEXT>
<TOKEN id="token-12-0" pos="unknown" morph="none" start_char="1666" end_char="1671">=.53).</TOKEN>
</SEG>
<SEG id="segment-13" start_char="1673" end_char="1774">
<ORIGINAL_TEXT>By day 21, symptoms had resolved for 82% of the ivermectin-treated group and 79% of the placebo group.</ORIGINAL_TEXT>
<TOKEN id="token-13-0" pos="word" morph="none" start_char="1673" end_char="1674">By</TOKEN>
<TOKEN id="token-13-1" pos="word" morph="none" start_char="1676" end_char="1678">day</TOKEN>
<TOKEN id="token-13-2" pos="word" morph="none" start_char="1680" end_char="1681">21</TOKEN>
<TOKEN id="token-13-3" pos="punct" morph="none" start_char="1682" end_char="1682">,</TOKEN>
<TOKEN id="token-13-4" pos="word" morph="none" start_char="1684" end_char="1691">symptoms</TOKEN>
<TOKEN id="token-13-5" pos="word" morph="none" start_char="1693" end_char="1695">had</TOKEN>
<TOKEN id="token-13-6" pos="word" morph="none" start_char="1697" end_char="1704">resolved</TOKEN>
<TOKEN id="token-13-7" pos="word" morph="none" start_char="1706" end_char="1708">for</TOKEN>
<TOKEN id="token-13-8" pos="word" morph="none" start_char="1710" end_char="1711">82</TOKEN>
<TOKEN id="token-13-9" pos="punct" morph="none" start_char="1712" end_char="1712">%</TOKEN>
<TOKEN id="token-13-10" pos="word" morph="none" start_char="1714" end_char="1715">of</TOKEN>
<TOKEN id="token-13-11" pos="word" morph="none" start_char="1717" end_char="1719">the</TOKEN>
<TOKEN id="token-13-12" pos="unknown" morph="none" start_char="1721" end_char="1738">ivermectin-treated</TOKEN>
<TOKEN id="token-13-13" pos="word" morph="none" start_char="1740" end_char="1744">group</TOKEN>
<TOKEN id="token-13-14" pos="word" morph="none" start_char="1746" end_char="1748">and</TOKEN>
<TOKEN id="token-13-15" pos="word" morph="none" start_char="1750" end_char="1751">79</TOKEN>
<TOKEN id="token-13-16" pos="punct" morph="none" start_char="1752" end_char="1752">%</TOKEN>
<TOKEN id="token-13-17" pos="word" morph="none" start_char="1754" end_char="1755">of</TOKEN>
<TOKEN id="token-13-18" pos="word" morph="none" start_char="1757" end_char="1759">the</TOKEN>
<TOKEN id="token-13-19" pos="word" morph="none" start_char="1761" end_char="1767">placebo</TOKEN>
<TOKEN id="token-13-20" pos="word" morph="none" start_char="1769" end_char="1773">group</TOKEN>
<TOKEN id="token-13-21" pos="punct" morph="none" start_char="1774" end_char="1774">.</TOKEN>
</SEG>
<SEG id="segment-14" start_char="1777" end_char="1882">
<ORIGINAL_TEXT>As for safety, adverse events were reported by 77% of the ivermectin group and 81.3% of the placebo group.</ORIGINAL_TEXT>
<TOKEN id="token-14-0" pos="word" morph="none" start_char="1777" end_char="1778">As</TOKEN>
<TOKEN id="token-14-1" pos="word" morph="none" start_char="1780" end_char="1782">for</TOKEN>
<TOKEN id="token-14-2" pos="word" morph="none" start_char="1784" end_char="1789">safety</TOKEN>
<TOKEN id="token-14-3" pos="punct" morph="none" start_char="1790" end_char="1790">,</TOKEN>
<TOKEN id="token-14-4" pos="word" morph="none" start_char="1792" end_char="1798">adverse</TOKEN>
<TOKEN id="token-14-5" pos="word" morph="none" start_char="1800" end_char="1805">events</TOKEN>
<TOKEN id="token-14-6" pos="word" morph="none" start_char="1807" end_char="1810">were</TOKEN>
<TOKEN id="token-14-7" pos="word" morph="none" start_char="1812" end_char="1819">reported</TOKEN>
<TOKEN id="token-14-8" pos="word" morph="none" start_char="1821" end_char="1822">by</TOKEN>
<TOKEN id="token-14-9" pos="word" morph="none" start_char="1824" end_char="1825">77</TOKEN>
<TOKEN id="token-14-10" pos="punct" morph="none" start_char="1826" end_char="1826">%</TOKEN>
<TOKEN id="token-14-11" pos="word" morph="none" start_char="1828" end_char="1829">of</TOKEN>
<TOKEN id="token-14-12" pos="word" morph="none" start_char="1831" end_char="1833">the</TOKEN>
<TOKEN id="token-14-13" pos="word" morph="none" start_char="1835" end_char="1844">ivermectin</TOKEN>
<TOKEN id="token-14-14" pos="word" morph="none" start_char="1846" end_char="1850">group</TOKEN>
<TOKEN id="token-14-15" pos="word" morph="none" start_char="1852" end_char="1854">and</TOKEN>
<TOKEN id="token-14-16" pos="unknown" morph="none" start_char="1856" end_char="1859">81.3</TOKEN>
<TOKEN id="token-14-17" pos="punct" morph="none" start_char="1860" end_char="1860">%</TOKEN>
<TOKEN id="token-14-18" pos="word" morph="none" start_char="1862" end_char="1863">of</TOKEN>
<TOKEN id="token-14-19" pos="word" morph="none" start_char="1865" end_char="1867">the</TOKEN>
<TOKEN id="token-14-20" pos="word" morph="none" start_char="1869" end_char="1875">placebo</TOKEN>
<TOKEN id="token-14-21" pos="word" morph="none" start_char="1877" end_char="1881">group</TOKEN>
<TOKEN id="token-14-22" pos="punct" morph="none" start_char="1882" end_char="1882">.</TOKEN>
</SEG>
<SEG id="segment-15" start_char="1884" end_char="1995">
<ORIGINAL_TEXT>Headache was the most common solicited adverse event (52% in the ivermectin group and 56% in the placebo group).</ORIGINAL_TEXT>
<TOKEN id="token-15-0" pos="word" morph="none" start_char="1884" end_char="1891">Headache</TOKEN>
<TOKEN id="token-15-1" pos="word" morph="none" start_char="1893" end_char="1895">was</TOKEN>
<TOKEN id="token-15-2" pos="word" morph="none" start_char="1897" end_char="1899">the</TOKEN>
<TOKEN id="token-15-3" pos="word" morph="none" start_char="1901" end_char="1904">most</TOKEN>
<TOKEN id="token-15-4" pos="word" morph="none" start_char="1906" end_char="1911">common</TOKEN>
<TOKEN id="token-15-5" pos="word" morph="none" start_char="1913" end_char="1921">solicited</TOKEN>
<TOKEN id="token-15-6" pos="word" morph="none" start_char="1923" end_char="1929">adverse</TOKEN>
<TOKEN id="token-15-7" pos="word" morph="none" start_char="1931" end_char="1935">event</TOKEN>
<TOKEN id="token-15-8" pos="punct" morph="none" start_char="1937" end_char="1937">(</TOKEN>
<TOKEN id="token-15-9" pos="word" morph="none" start_char="1938" end_char="1939">52</TOKEN>
<TOKEN id="token-15-10" pos="punct" morph="none" start_char="1940" end_char="1940">%</TOKEN>
<TOKEN id="token-15-11" pos="word" morph="none" start_char="1942" end_char="1943">in</TOKEN>
<TOKEN id="token-15-12" pos="word" morph="none" start_char="1945" end_char="1947">the</TOKEN>
<TOKEN id="token-15-13" pos="word" morph="none" start_char="1949" end_char="1958">ivermectin</TOKEN>
<TOKEN id="token-15-14" pos="word" morph="none" start_char="1960" end_char="1964">group</TOKEN>
<TOKEN id="token-15-15" pos="word" morph="none" start_char="1966" end_char="1968">and</TOKEN>
<TOKEN id="token-15-16" pos="word" morph="none" start_char="1970" end_char="1971">56</TOKEN>
<TOKEN id="token-15-17" pos="punct" morph="none" start_char="1972" end_char="1972">%</TOKEN>
<TOKEN id="token-15-18" pos="word" morph="none" start_char="1974" end_char="1975">in</TOKEN>
<TOKEN id="token-15-19" pos="word" morph="none" start_char="1977" end_char="1979">the</TOKEN>
<TOKEN id="token-15-20" pos="word" morph="none" start_char="1981" end_char="1987">placebo</TOKEN>
<TOKEN id="token-15-21" pos="word" morph="none" start_char="1989" end_char="1993">group</TOKEN>
<TOKEN id="token-15-22" pos="punct" morph="none" start_char="1994" end_char="1995">).</TOKEN>
</SEG>
<SEG id="segment-16" start_char="1998" end_char="2233">
<ORIGINAL_TEXT>The authors noted several limitations of the trial including a change in study design 6 weeks in (the original outcome measure was meant to assess clinical deterioration), a lack of virological assessments, and a young study population.</ORIGINAL_TEXT>
<TOKEN id="token-16-0" pos="word" morph="none" start_char="1998" end_char="2000">The</TOKEN>
<TOKEN id="token-16-1" pos="word" morph="none" start_char="2002" end_char="2008">authors</TOKEN>
<TOKEN id="token-16-2" pos="word" morph="none" start_char="2010" end_char="2014">noted</TOKEN>
<TOKEN id="token-16-3" pos="word" morph="none" start_char="2016" end_char="2022">several</TOKEN>
<TOKEN id="token-16-4" pos="word" morph="none" start_char="2024" end_char="2034">limitations</TOKEN>
<TOKEN id="token-16-5" pos="word" morph="none" start_char="2036" end_char="2037">of</TOKEN>
<TOKEN id="token-16-6" pos="word" morph="none" start_char="2039" end_char="2041">the</TOKEN>
<TOKEN id="token-16-7" pos="word" morph="none" start_char="2043" end_char="2047">trial</TOKEN>
<TOKEN id="token-16-8" pos="word" morph="none" start_char="2049" end_char="2057">including</TOKEN>
<TOKEN id="token-16-9" pos="word" morph="none" start_char="2059" end_char="2059">a</TOKEN>
<TOKEN id="token-16-10" pos="word" morph="none" start_char="2061" end_char="2066">change</TOKEN>
<TOKEN id="token-16-11" pos="word" morph="none" start_char="2068" end_char="2069">in</TOKEN>
<TOKEN id="token-16-12" pos="word" morph="none" start_char="2071" end_char="2075">study</TOKEN>
<TOKEN id="token-16-13" pos="word" morph="none" start_char="2077" end_char="2082">design</TOKEN>
<TOKEN id="token-16-14" pos="word" morph="none" start_char="2084" end_char="2084">6</TOKEN>
<TOKEN id="token-16-15" pos="word" morph="none" start_char="2086" end_char="2090">weeks</TOKEN>
<TOKEN id="token-16-16" pos="word" morph="none" start_char="2092" end_char="2093">in</TOKEN>
<TOKEN id="token-16-17" pos="punct" morph="none" start_char="2095" end_char="2095">(</TOKEN>
<TOKEN id="token-16-18" pos="word" morph="none" start_char="2096" end_char="2098">the</TOKEN>
<TOKEN id="token-16-19" pos="word" morph="none" start_char="2100" end_char="2107">original</TOKEN>
<TOKEN id="token-16-20" pos="word" morph="none" start_char="2109" end_char="2115">outcome</TOKEN>
<TOKEN id="token-16-21" pos="word" morph="none" start_char="2117" end_char="2123">measure</TOKEN>
<TOKEN id="token-16-22" pos="word" morph="none" start_char="2125" end_char="2127">was</TOKEN>
<TOKEN id="token-16-23" pos="word" morph="none" start_char="2129" end_char="2133">meant</TOKEN>
<TOKEN id="token-16-24" pos="word" morph="none" start_char="2135" end_char="2136">to</TOKEN>
<TOKEN id="token-16-25" pos="word" morph="none" start_char="2138" end_char="2143">assess</TOKEN>
<TOKEN id="token-16-26" pos="word" morph="none" start_char="2145" end_char="2152">clinical</TOKEN>
<TOKEN id="token-16-27" pos="word" morph="none" start_char="2154" end_char="2166">deterioration</TOKEN>
<TOKEN id="token-16-28" pos="punct" morph="none" start_char="2167" end_char="2168">),</TOKEN>
<TOKEN id="token-16-29" pos="word" morph="none" start_char="2170" end_char="2170">a</TOKEN>
<TOKEN id="token-16-30" pos="word" morph="none" start_char="2172" end_char="2175">lack</TOKEN>
<TOKEN id="token-16-31" pos="word" morph="none" start_char="2177" end_char="2178">of</TOKEN>
<TOKEN id="token-16-32" pos="word" morph="none" start_char="2180" end_char="2190">virological</TOKEN>
<TOKEN id="token-16-33" pos="word" morph="none" start_char="2192" end_char="2202">assessments</TOKEN>
<TOKEN id="token-16-34" pos="punct" morph="none" start_char="2203" end_char="2203">,</TOKEN>
<TOKEN id="token-16-35" pos="word" morph="none" start_char="2205" end_char="2207">and</TOKEN>
<TOKEN id="token-16-36" pos="word" morph="none" start_char="2209" end_char="2209">a</TOKEN>
<TOKEN id="token-16-37" pos="word" morph="none" start_char="2211" end_char="2215">young</TOKEN>
<TOKEN id="token-16-38" pos="word" morph="none" start_char="2217" end_char="2221">study</TOKEN>
<TOKEN id="token-16-39" pos="word" morph="none" start_char="2223" end_char="2232">population</TOKEN>
<TOKEN id="token-16-40" pos="punct" morph="none" start_char="2233" end_char="2233">.</TOKEN>
</SEG>
<SEG id="segment-17" start_char="2236" end_char="2457">
<ORIGINAL_TEXT>"The findings do not support the use of ivermectin for treatment of mild COVID-19, although larger trials may be needed to understand the effects of ivermectin on other clinically relevant outcomes," the authors concluded.</ORIGINAL_TEXT>
<TOKEN id="token-17-0" pos="punct" morph="none" start_char="2236" end_char="2236">"</TOKEN>
<TOKEN id="token-17-1" pos="word" morph="none" start_char="2237" end_char="2239">The</TOKEN>
<TOKEN id="token-17-2" pos="word" morph="none" start_char="2241" end_char="2248">findings</TOKEN>
<TOKEN id="token-17-3" pos="word" morph="none" start_char="2250" end_char="2251">do</TOKEN>
<TOKEN id="token-17-4" pos="word" morph="none" start_char="2253" end_char="2255">not</TOKEN>
<TOKEN id="token-17-5" pos="word" morph="none" start_char="2257" end_char="2263">support</TOKEN>
<TOKEN id="token-17-6" pos="word" morph="none" start_char="2265" end_char="2267">the</TOKEN>
<TOKEN id="token-17-7" pos="word" morph="none" start_char="2269" end_char="2271">use</TOKEN>
<TOKEN id="token-17-8" pos="word" morph="none" start_char="2273" end_char="2274">of</TOKEN>
<TOKEN id="token-17-9" pos="word" morph="none" start_char="2276" end_char="2285">ivermectin</TOKEN>
<TOKEN id="token-17-10" pos="word" morph="none" start_char="2287" end_char="2289">for</TOKEN>
<TOKEN id="token-17-11" pos="word" morph="none" start_char="2291" end_char="2299">treatment</TOKEN>
<TOKEN id="token-17-12" pos="word" morph="none" start_char="2301" end_char="2302">of</TOKEN>
<TOKEN id="token-17-13" pos="word" morph="none" start_char="2304" end_char="2307">mild</TOKEN>
<TOKEN id="token-17-14" pos="unknown" morph="none" start_char="2309" end_char="2316">COVID-19</TOKEN>
<TOKEN id="token-17-15" pos="punct" morph="none" start_char="2317" end_char="2317">,</TOKEN>
<TOKEN id="token-17-16" pos="word" morph="none" start_char="2319" end_char="2326">although</TOKEN>
<TOKEN id="token-17-17" pos="word" morph="none" start_char="2328" end_char="2333">larger</TOKEN>
<TOKEN id="token-17-18" pos="word" morph="none" start_char="2335" end_char="2340">trials</TOKEN>
<TOKEN id="token-17-19" pos="word" morph="none" start_char="2342" end_char="2344">may</TOKEN>
<TOKEN id="token-17-20" pos="word" morph="none" start_char="2346" end_char="2347">be</TOKEN>
<TOKEN id="token-17-21" pos="word" morph="none" start_char="2349" end_char="2354">needed</TOKEN>
<TOKEN id="token-17-22" pos="word" morph="none" start_char="2356" end_char="2357">to</TOKEN>
<TOKEN id="token-17-23" pos="word" morph="none" start_char="2359" end_char="2368">understand</TOKEN>
<TOKEN id="token-17-24" pos="word" morph="none" start_char="2370" end_char="2372">the</TOKEN>
<TOKEN id="token-17-25" pos="word" morph="none" start_char="2374" end_char="2380">effects</TOKEN>
<TOKEN id="token-17-26" pos="word" morph="none" start_char="2382" end_char="2383">of</TOKEN>
<TOKEN id="token-17-27" pos="word" morph="none" start_char="2385" end_char="2394">ivermectin</TOKEN>
<TOKEN id="token-17-28" pos="word" morph="none" start_char="2396" end_char="2397">on</TOKEN>
<TOKEN id="token-17-29" pos="word" morph="none" start_char="2399" end_char="2403">other</TOKEN>
<TOKEN id="token-17-30" pos="word" morph="none" start_char="2405" end_char="2414">clinically</TOKEN>
<TOKEN id="token-17-31" pos="word" morph="none" start_char="2416" end_char="2423">relevant</TOKEN>
<TOKEN id="token-17-32" pos="word" morph="none" start_char="2425" end_char="2432">outcomes</TOKEN>
<TOKEN id="token-17-33" pos="punct" morph="none" start_char="2433" end_char="2434">,"</TOKEN>
<TOKEN id="token-17-34" pos="word" morph="none" start_char="2436" end_char="2438">the</TOKEN>
<TOKEN id="token-17-35" pos="word" morph="none" start_char="2440" end_char="2446">authors</TOKEN>
<TOKEN id="token-17-36" pos="word" morph="none" start_char="2448" end_char="2456">concluded</TOKEN>
<TOKEN id="token-17-37" pos="punct" morph="none" start_char="2457" end_char="2457">.</TOKEN>
</SEG>
<SEG id="segment-18" start_char="2460" end_char="2569">
<ORIGINAL_TEXT>Disclosure: Some authors have declared affiliations with or received funding from the pharmaceutical industry.</ORIGINAL_TEXT>
<TOKEN id="token-18-0" pos="word" morph="none" start_char="2460" end_char="2469">Disclosure</TOKEN>
<TOKEN id="token-18-1" pos="punct" morph="none" start_char="2470" end_char="2470">:</TOKEN>
<TOKEN id="token-18-2" pos="word" morph="none" start_char="2472" end_char="2475">Some</TOKEN>
<TOKEN id="token-18-3" pos="word" morph="none" start_char="2477" end_char="2483">authors</TOKEN>
<TOKEN id="token-18-4" pos="word" morph="none" start_char="2485" end_char="2488">have</TOKEN>
<TOKEN id="token-18-5" pos="word" morph="none" start_char="2490" end_char="2497">declared</TOKEN>
<TOKEN id="token-18-6" pos="word" morph="none" start_char="2499" end_char="2510">affiliations</TOKEN>
<TOKEN id="token-18-7" pos="word" morph="none" start_char="2512" end_char="2515">with</TOKEN>
<TOKEN id="token-18-8" pos="word" morph="none" start_char="2517" end_char="2518">or</TOKEN>
<TOKEN id="token-18-9" pos="word" morph="none" start_char="2520" end_char="2527">received</TOKEN>
<TOKEN id="token-18-10" pos="word" morph="none" start_char="2529" end_char="2535">funding</TOKEN>
<TOKEN id="token-18-11" pos="word" morph="none" start_char="2537" end_char="2540">from</TOKEN>
<TOKEN id="token-18-12" pos="word" morph="none" start_char="2542" end_char="2544">the</TOKEN>
<TOKEN id="token-18-13" pos="word" morph="none" start_char="2546" end_char="2559">pharmaceutical</TOKEN>
<TOKEN id="token-18-14" pos="word" morph="none" start_char="2561" end_char="2568">industry</TOKEN>
<TOKEN id="token-18-15" pos="punct" morph="none" start_char="2569" end_char="2569">.</TOKEN>
</SEG>
<SEG id="segment-19" start_char="2571" end_char="2636">
<ORIGINAL_TEXT>Please refer to the original study for a full list of disclosures.</ORIGINAL_TEXT>
<TOKEN id="token-19-0" pos="word" morph="none" start_char="2571" end_char="2576">Please</TOKEN>
<TOKEN id="token-19-1" pos="word" morph="none" start_char="2578" end_char="2582">refer</TOKEN>
<TOKEN id="token-19-2" pos="word" morph="none" start_char="2584" end_char="2585">to</TOKEN>
<TOKEN id="token-19-3" pos="word" morph="none" start_char="2587" end_char="2589">the</TOKEN>
<TOKEN id="token-19-4" pos="word" morph="none" start_char="2591" end_char="2598">original</TOKEN>
<TOKEN id="token-19-5" pos="word" morph="none" start_char="2600" end_char="2604">study</TOKEN>
<TOKEN id="token-19-6" pos="word" morph="none" start_char="2606" end_char="2608">for</TOKEN>
<TOKEN id="token-19-7" pos="word" morph="none" start_char="2610" end_char="2610">a</TOKEN>
<TOKEN id="token-19-8" pos="word" morph="none" start_char="2612" end_char="2615">full</TOKEN>
<TOKEN id="token-19-9" pos="word" morph="none" start_char="2617" end_char="2620">list</TOKEN>
<TOKEN id="token-19-10" pos="word" morph="none" start_char="2622" end_char="2623">of</TOKEN>
<TOKEN id="token-19-11" pos="word" morph="none" start_char="2625" end_char="2635">disclosures</TOKEN>
<TOKEN id="token-19-12" pos="punct" morph="none" start_char="2636" end_char="2636">.</TOKEN>
</SEG>
<SEG id="segment-20" start_char="2640" end_char="2648">
<ORIGINAL_TEXT>Reference</ORIGINAL_TEXT>
<TOKEN id="token-20-0" pos="word" morph="none" start_char="2640" end_char="2648">Reference</TOKEN>
</SEG>
<SEG id="segment-21" start_char="2652" end_char="2694">
<ORIGINAL_TEXT>López-Medina E, López P, Hurtado IC, et al.</ORIGINAL_TEXT>
<TOKEN id="token-21-0" pos="unknown" morph="none" start_char="2652" end_char="2663">López-Medina</TOKEN>
<TOKEN id="token-21-1" pos="word" morph="none" start_char="2665" end_char="2665">E</TOKEN>
<TOKEN id="token-21-2" pos="punct" morph="none" start_char="2666" end_char="2666">,</TOKEN>
<TOKEN id="token-21-3" pos="word" morph="none" start_char="2668" end_char="2672">López</TOKEN>
<TOKEN id="token-21-4" pos="word" morph="none" start_char="2674" end_char="2674">P</TOKEN>
<TOKEN id="token-21-5" pos="punct" morph="none" start_char="2675" end_char="2675">,</TOKEN>
<TOKEN id="token-21-6" pos="word" morph="none" start_char="2677" end_char="2683">Hurtado</TOKEN>
<TOKEN id="token-21-7" pos="word" morph="none" start_char="2685" end_char="2686">IC</TOKEN>
<TOKEN id="token-21-8" pos="punct" morph="none" start_char="2687" end_char="2687">,</TOKEN>
<TOKEN id="token-21-9" pos="word" morph="none" start_char="2689" end_char="2690">et</TOKEN>
<TOKEN id="token-21-10" pos="word" morph="none" start_char="2692" end_char="2693">al</TOKEN>
<TOKEN id="token-21-11" pos="punct" morph="none" start_char="2694" end_char="2694">.</TOKEN>
</SEG>
<SEG id="segment-22" start_char="2696" end_char="2782">
<ORIGINAL_TEXT>Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19.</ORIGINAL_TEXT>
<TOKEN id="token-22-0" pos="word" morph="none" start_char="2696" end_char="2701">Effect</TOKEN>
<TOKEN id="token-22-1" pos="word" morph="none" start_char="2703" end_char="2704">of</TOKEN>
<TOKEN id="token-22-2" pos="word" morph="none" start_char="2706" end_char="2715">ivermectin</TOKEN>
<TOKEN id="token-22-3" pos="word" morph="none" start_char="2717" end_char="2718">on</TOKEN>
<TOKEN id="token-22-4" pos="word" morph="none" start_char="2720" end_char="2723">time</TOKEN>
<TOKEN id="token-22-5" pos="word" morph="none" start_char="2725" end_char="2726">to</TOKEN>
<TOKEN id="token-22-6" pos="word" morph="none" start_char="2728" end_char="2737">resolution</TOKEN>
<TOKEN id="token-22-7" pos="word" morph="none" start_char="2739" end_char="2740">of</TOKEN>
<TOKEN id="token-22-8" pos="word" morph="none" start_char="2742" end_char="2749">symptoms</TOKEN>
<TOKEN id="token-22-9" pos="word" morph="none" start_char="2751" end_char="2755">among</TOKEN>
<TOKEN id="token-22-10" pos="word" morph="none" start_char="2757" end_char="2762">adults</TOKEN>
<TOKEN id="token-22-11" pos="word" morph="none" start_char="2764" end_char="2767">with</TOKEN>
<TOKEN id="token-22-12" pos="word" morph="none" start_char="2769" end_char="2772">mild</TOKEN>
<TOKEN id="token-22-13" pos="unknown" morph="none" start_char="2774" end_char="2781">COVID-19</TOKEN>
<TOKEN id="token-22-14" pos="punct" morph="none" start_char="2782" end_char="2782">.</TOKEN>
</SEG>
<SEG id="segment-23" start_char="2784" end_char="2816">
<ORIGINAL_TEXT>[Published online March 4, 2021].</ORIGINAL_TEXT>
<TOKEN id="token-23-0" pos="punct" morph="none" start_char="2784" end_char="2784">[</TOKEN>
<TOKEN id="token-23-1" pos="word" morph="none" start_char="2785" end_char="2793">Published</TOKEN>
<TOKEN id="token-23-2" pos="word" morph="none" start_char="2795" end_char="2800">online</TOKEN>
<TOKEN id="token-23-3" pos="word" morph="none" start_char="2802" end_char="2806">March</TOKEN>
<TOKEN id="token-23-4" pos="word" morph="none" start_char="2808" end_char="2808">4</TOKEN>
<TOKEN id="token-23-5" pos="punct" morph="none" start_char="2809" end_char="2809">,</TOKEN>
<TOKEN id="token-23-6" pos="word" morph="none" start_char="2811" end_char="2814">2021</TOKEN>
<TOKEN id="token-23-7" pos="punct" morph="none" start_char="2815" end_char="2816">].</TOKEN>
</SEG>
<SEG id="segment-24" start_char="2819" end_char="2822">
<ORIGINAL_TEXT>JAMA</ORIGINAL_TEXT>
<TOKEN id="token-24-0" pos="word" morph="none" start_char="2819" end_char="2822">JAMA</TOKEN>
</SEG>
<SEG id="segment-25" start_char="2825" end_char="2851">
<ORIGINAL_TEXT>doi:10.1001/jama.2021.3071.</ORIGINAL_TEXT>
<TOKEN id="token-25-0" pos="unknown" morph="none" start_char="2825" end_char="2850">doi:10.1001/jama.2021.3071</TOKEN>
<TOKEN id="token-25-1" pos="punct" morph="none" start_char="2851" end_char="2851">.</TOKEN>
</SEG>
<SEG id="segment-26" start_char="2854" end_char="2892">
<ORIGINAL_TEXT>This article originally appeared on MPR</ORIGINAL_TEXT>
<TOKEN id="token-26-0" pos="word" morph="none" start_char="2854" end_char="2857">This</TOKEN>
<TOKEN id="token-26-1" pos="word" morph="none" start_char="2859" end_char="2865">article</TOKEN>
<TOKEN id="token-26-2" pos="word" morph="none" start_char="2867" end_char="2876">originally</TOKEN>
<TOKEN id="token-26-3" pos="word" morph="none" start_char="2878" end_char="2885">appeared</TOKEN>
<TOKEN id="token-26-4" pos="word" morph="none" start_char="2887" end_char="2888">on</TOKEN>
<TOKEN id="token-26-5" pos="word" morph="none" start_char="2890" end_char="2892">MPR</TOKEN>
</SEG>
</TEXT>
</DOC>
</LCTL_TEXT>
